Greater clinical benefit in controlling the symptoms of asthma is frequently observed through combining moderate doses of inhaled glucocorticoids together with long-acting ␤ 2 -agonists, as compared with increasing glucocorticoid dosage alone. To address in vitro whether glucocorticoids plus ␤ 2 -agonists, compared with glucocorticoids alone, have greater inhibitory activity on CD4ϩ T cell responses to allergen, peripheral blood CD4ϩ T cell responses to allergen were compared in the presence or absence of the glucocorticoid fluticasone proprionate and the short-and long-acting ␤ 2 -agonists salbutamol and salmeterol, respectively. 
increasing evidence that ␤ 2 -agonists are able to affect functions of T cells and other leukocytes, at least in vitro (8) .
Previous clinical studies have shown that, in patients whose asthma symptoms cannot be controlled by moderate dosages of inhaled glucocorticoid, further clinical benefit can be achieved by additional treatment with a long-acting ␤ 2 -agonist, rather than by solely continuing to increase the glucocorticoid dosage (9) (10) (11) . The mechanism of this phenomenon remains unexplained (12) .
One mechanism by which glucocorticoids may inhibit T cell function is through the induction of the anti-inflammatory cytokine IL-10 (13, 14) . We previously documented the capacity of glucocorticoids to induce regulatory T cells expressing relatively large quantities of the anti-inflammatory cytokine IL-10, but relatively small quantities of Th1 and Th2 cytokines. These cells were capable of inhibiting, or regulating, autologous T cell responses in an IL-10-dependent manner (15) . We recently also demonstrated that glucocorticoid-induced IL-10 synthesis is deficient in peripheral blood T cells from patients clinically resistant to glucocorticoid therapy (16) , supporting the hypothesis that induction of IL-10 may contribute to the clinical efficacy of glucocorticoid therapy.
Based on these observations, we hypothesized that the combination of a long-acting ␤ 2 -agonist with a glucocorticoid results in greater inhibition of allergen-driven Th2 effector responses and enhanced production of IL-10 by human CD4ϩ T cells when compared with glucocorticoids alone.
MATERIALS AND METHODS

Patients
Atopy was defined as a positive wheal at 15 min after skin prick testing to у 1 of a panel of aeroallergens (cat, grass, and house dust mite, Soluprick; ALK, Horsholm, Denmark) performed with diluent and histamine controls in individuals with a clinical history of allergy. All subjects (9 male, 15 female atopic; 1 male, 6 female nonatopic) were between 20 and 48 yr old. The study was approved by Guy's Hospital Ethics Committee and full written informed consent obtained from all subjects before study.
Cell Purification
Peripheral blood mononuclear cells (PBMC) were isolated using Lymphoprep (Nycomed, Birmingham, UK) and depleted of CD8ϩ T cells or enriched for CD4ϩ T cells using antibody-conjugated magnetic beads (Dynal, Wirral, UK). Cells were cultured in RPMI 1640 (Life Sciences, Abingdon, UK), containing 5% heat-inactivated human AB serum (National Blood Service, London, UK), 2 mM l-glutamine and 50 g/ml gentamycin (Life Sciences). In studies to generate T cell lines and in which T cell function was tested, irradiated (4,000 rads) T cell-depleted PBMC were used as antigen-presenting cells (APC).
Allergen Stimulation Cultures
CD8ϩ T cell depleted PBMC were cultured at 2 ϫ 10 6 cells/ml with 10 g/ml of the relevant allergen (house dust mite, grass, or cat extract, Aquagen; ALK) and 10 ng/ml IL-4 (NBS, Hatfield, UK). Fluticasone proprionate (GlaxoSmithKline, Stevenage, UK), salmeterol, salbutamol (both Sigma-Aldrich, Poole, UK), and the ␤ 2 -adrenoreceptor antagonist ICI 118,551 (Tocris, Bristol, UK) were added as indicated. Day 7 culture supernatants were analyzed for cytokine content.
Generation of Allergen-Specific T Cell Lines
For Th2 lines, CD4ϩ T cells plus APC were cultured with 10 g/ml allergen and 10ng/ml IL-4 plus neutralizing antibodies to human interferon (IFN)-␥ and IL-12 (BD-Pharmingen, Abingdon, UK). For regulatory T cell lines, CD4 ϩ T cells plus APC were cultured with 10 g/ml allergen, 10 ng/ml IL-4, 10 Ϫ9 M fluticasone proprionate and 10 Ϫ6 M salmeterol (T Flut/Sal ). Both lines were cultured for 7 d, then restimulated at a 1:1 ratio with irradiated autologous APC under identical conditions as the original culture. The lines underwent two rounds of stimulation and then supernatants were harvested for cytokine analysis. To assay regulatory/suppressive activity, cells were harvested at 14 d. Cultures contained the indicated combinations of 10 5 Th2 cells, 2.5 ϫ 10 4 T Flut/Sal line cells, 10 g/ml specific allergen, 5 g/ml anti-IL-10 receptor (3F9-2, DNAX, CA) or 5 g/ml control antibody (R35-9S; BDPharmingen). All wells contained 10 5 irradiated autologous APC. On Day 3, 100 l supernatant was removed for cytokine measurement.
Cytokine Measurement
IL-5, IL-10, IL-13, and IFN-␥ were measured by enzyme-linked immunosorbent assay (ELISA) (limits of detection for IFN-␥, IL-10 50 pg/ml; IL-5 and IL-13, 100 pg/ml; Pharmingen). When р 100 l of supernatant was available, concentrations were determined using the BD Th1/Th2 cytometric bead array kit and a FACsCalibar flow cytometer (Becton Dickinson, Abingdon, UK). For intracellular cytokine expression, CD4ϩ T cells were stimulated with plate-bound anti-CD3, soluble anti-CD28 (with or without salmeterol and/or fluticasone proprionate for 7 d), restimulated with phorbol ester (0.25 ng/ml; Sigma), ionomycin (25 ng/ml; Calbiochem, Beeston, UK) for 4 h with monensin (Sigma), Figure 1 . Long-acting ␤ 2 -agonists and glucocorticoids inhibit Th2 responses to allergen. Data are expressed as mean Ϯ SEM amount cytokine (left-hand side) and as a percentage of the allergen-induced production (right-hand side). Atopic group n ϭ 11 and non-atopic group n ϭ 9. # P р 0.05 comparable groups with and without allergen, **P р 0.01 *P р 0.05 groups compared with allergen alone.
then stained using reagents (IL-13PE clone JES10-5A2; IL-10APC clone JES3-19F1 and control rat IgG1PE and rat IgG2aAPC antibody reagents) from BD-Pharmingen, as previously described (15) .
Statistical Analysis
Results are presented as means Ϯ SEM. Differences between groups were assessed using the Student's paired t test (17) . Differences were considered significant at the 95% confidence level. Figure 1 , left-hand panels) and atopic donors synthesized much higher levels of cytokine compared with nonatopic donors, as predicted from earlier published reports (1, 2, 18) .
RESULTS
As the magnitude of the allergen-induced response varied between individuals, the effects of drugs on IL-13 production were expressed as percentages of the positive control response ( Figure 1 , right-hand panels). In atopic individuals, fluticasone proprionate alone caused a concentration-dependent inhibition of IL-13 production, which was significant at a concentration 10 Ϫ9 M or greater (IL-13 10 Ϫ8 M, P р 0.01; IL-13 10 Ϫ9 M, P р 0.05). This inhibition was more profound in nonatopic individuals, where the magnitude of the response to allergen was Ͼ 6-fold lower than that seen in the atopic individuals (10 Ϫ8 M and 10 Ϫ9 M, P р 0.01; 10 Ϫ10 M, P р 0.05) Similar data were observed with IL-5 (data not shown).
Salmeterol alone (10 Ϫ6 M) also significantly inhibited production of IL-13 at 10 Ϫ6 M (P р 0.01), 10 Ϫ7 M, and 10 Ϫ8 M (both P р 0.05) concentrations in atopic individuals. Significant inhibition of the IL-13 response was also observed in nonatopic individuals at 10 Ϫ6 M salmeterol (P р 0.05), but not at lower concentrations of the drug. This may be due to the low and variable Th2 response by these subjects to allergen. After initial titration experiments, salmeterol was used at 10 Ϫ6 M in all further experiments.
The effects of fluticasone proprionate and salmeterol on Th2 cytokine responses were tested in combination in atopic individuals, as this group demonstrated robust Th2 responses to allergen in culture. The two drugs showed an approximately additive effect in inhibiting both IL-13 and IL-5 production (Figure 2) . Thus, at concentrations of fluticasone proprionate significantly effective alone (10 Ϫ8 M, 10 Ϫ9 M), the addition of salmeterol (10 Ϫ6 M) virtually abolished cytokine production, whereas with lower concentrations of fluticasone proprionate the combined effect approximated to that of salmeterol alone.
Long-Acting but Not Short-Acting ␤ 2 -Agonist Inhibits Allergen-Induced Th2 Responses: Dependence on ␤ 2 -Adrenoreceptor Stimulation
In contrast to salmeterol, the short-acting ␤ 2 -agonist salbutamol (albuterol) at an equivalent concentration (10 Ϫ6 M) showed no significant inhibitory affect on allergen-induced production of IL-13 and IL-5. Furthermore, it did not add to the inhibitory effect of fluticasone proprionate ( Figure 3A) . Nevertheless, the inhibitory affect of salmeterol was exerted through the ␤ 2 -adrenoreceptor, because addition of the selective ␤ 2 -adrenoreceptor antagonist ICI 118.551 (10 Ϫ6 M) fully reversed the inhibitory effect of salmeterol on allergen-induced IL-13 and IL-5 production ( Figure 3B , lefthand panel, and data not shown).
Both Long-Acting ␤ 2 -Agonists and Glucocorticoids Enhance Allergen-Induced IL-10 Production
Allergen stimulation alone induced only low levels of IL-10 synthesis by CD8ϩ T cell-depleted peripheral blood mononuclear cells above medium control (medium control 56 Ϯ 16 pg/ml versus with allergen 168 Ϯ 42 pg/ml; n ϭ 10; P р 0.05). Addition of fluticasone proprionate to the allergen-stimulated cultures induced a concentration-dependent enhancement of IL-10 production, which was significant at a concentration of 10 Ϫ10 M or greater (10 Ϫ8 M and 10 Ϫ9 M, P р 0.01; 10 Ϫ10 M, P р 0.05). Salmeterol alone also enhanced IL-10 production, which reached statistical significance at 10 Ϫ6 M (P р 0.01) but not at lower concentrations of the drug ( Figure 4A and data not shown). Again this effect appeared to be mediated through ␤ 2 -adrenoreceptor stimulation, since it was abrogated in the presence of the selective ␤ 2 -adrenoreceptor antagonist ICI 118.551 (10 Ϫ6 M) ( Figure 3B ). Salmeterol failed to increase IL-10 production further in the presence of the two highest concentrations of fluticasone proprionate, but did show an additive effect on IL-10 production at lower fluticasone proprionate concentrations ( Figure 4A ).
Allergen-specific T cells are present at a very low frequency in these cultures. In order, therefore, to directly visualize the effects of fluticasone proprionate and salmeterol on the number of IL-10-secreting cells, purified CD4 ϩ T cells were stimulated by the polyclonal T cell activator anti-CD3 together with anti-CD28 in the absence of APC. Figure 4B shows a typical experiment representative of three. Both salmeterol (10 Ϫ6 M) and fluticasone proprionate (10 Ϫ9 M) independently increased the frequency of IL-10-immunoreactive cells, and the combined effect of the two drugs was approximately additive. The pattern of inhibition of IL-13 expression by salmeterol and fluticasone proprionate, singly and in combination, was similar to that observed by ELISA.
Generation of Allergen-Specific, Functional T Regulatory Cell Lines in the Presence of Long-Acting ␤ 2 -Agonists and Glucocorticoids
To address whether enhanced IL-10 synthesis induced by combined drug treatment resulted in inhibitory or regulatory activity, allergen-specific T cell lines were generated from CD8ϩ T celldepleted peripheral blood mononuclear cells in the presence of these two drugs. Th2-polarized allergen-specific effector lines were also generated from the same individuals in parallel. Both lines underwent two rounds of stimulation, and cell recoveries were not significantly different between the two cell lines following both the first and second rounds of culture (data not shown). As compared with the Th2-polarized lines, IL-5 and IL-13 production in culture supernatants of lines raised in the presence of the two drugs (T Flut/Sal ) was significantly reduced (P р 0.01), while that of IL-10 was increased ( Figure 5 ), although this was not statistically significant. The difference in the cytokine profiles of these two types of T cell line was most striking when compared as a ratio of IL-5 or IL-13 to IL-10 (Th 2 versus T Flut/Sal ratios for IL-5:IL-10 were 3.18 versus 0.12, and for IL-13:IL-10 were 7.62 versus 0.52, respectively). Thus, the combination of salmeterol and fluticasone proprionate skewed these cell lines toward an IL-10-expressing T regulatory phenotype.
The inhibitory properties of these putative T regulatory lines was investigated by co-culturing them together with cells from autologous Th2 effector lines, irradiated APC, and allergen for 3 d. When cultured alone, the Th2 line produced IL-5 and IL-13 in response to allergen as before, and the regulatory T line produced little or none ( Figure 6A ). The two lines were cocultured at a ratio of four Th2 cells to one regulatory T cell, a ratio calculated to be optimal based on earlier studies in an anti-CD3-driven system (data not shown). In this co-culture the production of IL-5 and IL-13 by the Th2 cells was abrogated ( Figure 6A ). Furthermore, culture in the presence of a blocking anti-IL-10 receptor antibody not only increased IL-13 production by the Th2 effector line alone, as predicted from earlier reports, but also reversed the inhibition of IL-13 production by the T regulatory cells in the co-culture experiments ( Figure 6B ).
DISCUSSION
We have shown that the long-acting ␤ 2 -agonist salmeterol, as well as the glucocorticoid fluticasone proprionate, can inhibit allergen-driven Th2 cytokine production by CD4ϩ T cells from atopic subjects. The effect of salmeterol was dependent on ␤ 2 -adrenoreceptor stimulation as demonstrated by its abrogation by a selective ␤ 2 -receptor antagonist. In contrast, the short-acting ␤ 2 -agonist salbutamol had no significant effect on cytokine synthesis under identical conditions. In addition, we have shown that high concentrations of salmeterol, as well as fluticasone proprionate, skew the cytokine profile of allergen-driven CD4ϩ T cells in atopic subjects from a Th2 phenotype toward a T regulatory phenotype, with elevated production of IL-10. Again, this phenomenon was abolished by ␤ 2 -receptor blockade. Allergenspecific T cell lines raised in the presence of fluticasone proprionate and salmeterol, in addition to producing elevated IL-10, were functionally active in suppressing syngeneic Th2 effector responses to allergen. Independent studies implicate IL-10 as an important anti-inflammatory cytokine in asthma and the lung (19) (20) (21) . The present study extends the beneficial mechanisms via which long-acting ␤ 2 -agonists and glucocorticoids may cooperate to greater therapeutic benefit in asthma by causing additive inhibition of Th2 cytokine production and enhancing synthesis of the anti-inflammatory cytokine IL-10.
The T cell-inhibitory effects of salmeterol documented in the present study are consistent with previous studies showing a range of inhibitory effects of this drug on cytokine production by T cells activated by mitogen or specific antigen (22) (23) (24) (25) (26) . Inhibition of Th2 cytokine secretion by basophils and mast cells by salmeterol has also been reported (reviewed in Ref. 8) . One very recent report (27) , however, failed to observe an inhibition of Th2 cytokine production by salmeterol alone using a slightly lower concentration of the drug. One additional difference between that and the present study is the use of mitogen versus allergen to stimulate a T cell response. The authors did, however, observe that combining salmeterol and fluticasone proprionate led to greater inhibition of both proliferation and Th2 cytokine production than either drug alone in healthy donors. The capacity of salmeterol to inhibit cytokine production by Th1 cells has been reported to reflect actions on APC (28) . In the current study, enhancement of IL-10 and inhibition of Th2 cytokine production may reflect both a direct effect on the T cell, since experiments to demonstrate changes in intracellular cytokine staining were performed using purified CD4ϩ T cell populations, and indirect effects at the level of the APC population which were present in all allergen-stimulated cultures.
Our findings suggest that the functional interaction between salmeterol and fluticasone proprionate, at least in terms of suppression of Th2 effector responses and the promotion of IL-10 synthesizing T cells, is seen at comparatively high concentrations of salmeterol but lower concentrations of fluticasone proprionate. This reflects the clinical situation in which combined treatment with inhaled, long-acting ␤ 2 -agonist and glucocorticoid at low dosage has clearly been shown to be advantageous in comparison with high dosages of glucocorticoid used alone (9, 10, 29) . It is tempting to speculate that this clinical effect reflects the collaborative inhibitory effect of long-acting ␤ 2 -agonist and glucocorticoid, which we have demonstrated in the present study. Studies on the anti-inflammatory affects of inhaled long acting ␤ 2 -agonist alone in asthma have produced variable results, with some studies reporting reduction in mucosal mast cells (10) , eosinophils (26, 30) , or neutrophils (31), and others reporting no effect at all (32) . These discrepancies most likely reflect the variable power of these studies to detect significant differences and systematic studies of possible collaborative effects of these two drugs on asthmatic bronchial inflammation in vivo are required to clarify this issue.
Our data suggest an additive, but not a synergistic effect of long-acting ␤ 2 -agonist and glucocorticoid on T cell effector and regulatory functions. Recent studies in the literature suggest the possibility of direct interactions between these drugs at the molecular level. Glucocorticoids increase the expression of ␤ 2 -adrenoreceptors by increasing transcription of their gene. This may theoretically counteract tachyphylaxis to ␤ 2 -adrenoreceptor stimulation caused by receptor internalization (10) . In addition, it has been suggested that ␤ 2 -agonists and glucocorticoids act on common transcriptional regulatory proteins (33) , and that ␤ 2 -agonist affects ligand-independent activation (possibly by phosphorylation) of the glucocorticoid receptor that facilitates nuclear translocation (reviewed in Ref. 10) . Experimental evidence is currently discordant as to whether or not this effect is confined to long-acting ␤ 2 -agonist or seen with both short-and long-acting ␤ 2 -agonist (34, 35). The present study was not designed to address these mechanistic questions, but does clearly demonstrate the potential for a collaborative anti-inflammatory effect of long-acting ␤ 2 -agonists and glucocorticoids on T cell-mediated processes thought to be critical to their therapeutic profile.
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